Kornimate/medical-research-clean huggingface dataset:
recombinant lh supplementation timing strategies (from day 1 or day 6) to a standard gnrh agonist long protocol in subsequent cos cycle of older patients with unexpected poor or suboptimal ovarian response

Conditions: Infertility,Female

Summary: a randomized, controlled, pilot study, for patients ≥ 35 years and \< 40 years old with sufficient ovarian reserve parameters (afc≥ 5), but showed an unexpected poor or suboptimal ovarian response(defined as ≤ 9 retrieved oocytes in previous full-stimulation cycle, but not get live birth after all embryos were used ). in order to get better oocyte number and quality in the new cos cycle, we will compare lh supplementation from beginning with from middle of stimulation in gnrh-a long protocol.


Eligibility criteria:
inclusion criteria: 1.infertile women, 35≤ age\< 40 years 2.18\<bmi\<28 kg/m2 3.5 ≤afc ≤20 4.basal serum fsh≤10 iu/l, e2\<70 pg/ml 5.previous cycle as the first cos cycle,afc ≥ 5,starting dose of fsh between 150 iu and 300iu with the possibility of adding r-hlh or hmg later in the cycle, number of oocytes retrieved ≤9 (4-9 oocytes retrieval as suboptimal responder and \<4 oocytes retrieval as unexpected poor responder), but not get live birth after all embryos were used. 6.normal uterus and at least one side of the normal ovary 7.gnrh-a long protocol, using gonal-f® 300iu and luveris® 150iu for cos 8.informed consent form signed 9.willing to follow the study protocol, and able to complete this study exclusion criteria: 1. moderate and severe endometriosis 2. pcos 3. previous ovarian surgery history 4. history of recurrent miscarriages (\>2 times of miscarriages) 5. any major systemic disease that as per investigator's discretion precludes subject for participation in the study 6. with pregnancy contraindications alcoholism, drug abuse, drug addiction or patients with uncured sexually transmitted disease 7. according to the judgment of the investigator, any medical condition or any concomitant surgery/medications that would interfere with evaluation of study medications 8. simultaneous participation in another clinical study 9. plan to use other gn other than gonal-f® or luveris® during cos treatment thyroid gland disorders

Keywords: poor or suboptimal ovarian response,gnrh agonist long protocol
effect of occlusal reduction on relief of pain and sensitivity to percussion in patients with irreversible pulpitis

Conditions: Post Operative Pain; Post-Op Complication

Summary: one of the most important aspects of endodontic practice is to abate pain during and post root canal treatment. an endodontist by all means should provide a painless endodontic treatment to their patients. this study is carried out to determine the effect of occlusal reduction on relief of pain and percussion in patients with irreversible pulpitis and symptomatic apical periodontitis treated in a single visit root canal treatment. pain will be assessed preoperatively and then post operatively after completion of the root canal at 6 hours, 12 hours, 24 hours, 48 hours and 72 hours following obturation of root canal.

the objective of this randomized clinical trial is to evaluate the impact of occlusal reduction on the incidence of post obturation pain. 56 patients will be allocated randomly into 2 groups keeping 28 patients in each group which will meet the inclusion criteria of the study, patients diagnosed with symptomatic irreversible pulpitis and symptomatic apical periodontitis and requiring porcelain fused to metal crown with age ranging from 18 to 50 years. in the interventional group 2mm reduction will be done and assessment will be done to confirm the absence of occlusal contact while in control group no modification will be carried out on the occlusal surface. single visit endodontic treatment will be carried out with 2.5% sodium hypochlorite for disinfection of the canal followed by crown down technique using rotary nickel titanium files for shaping the canals followed by obturating the canals with lateral condensation technique. pain will be assessed preoperatively and then post operatively at 6 hours, 12 hours, 24 hours, 48 hours and 72 hours following obturation of root canal. visual analogue scale (vas) will be used as a primary outcome measure.the vas consists of a 10-cm line having two extremes no pain and extreme pain. patients will be asked to choose the mark that represents their level of pain at the intervals mentioned above . pain level are assigned to one of four categorical scores 1, none(0); 2, mild (1-3) ; 3 moderate (4-6); 4, severe (7-10) 10. tenderness to percussion will be evaluated postoperatively at 48 hour with readings either positive to tenderness or negative to tenderness positive to tenderness will evaluate treatment not effective negative to tenderness at 48 hour post obturation will evaluate treatment effectiveness patients will be given placebo for administration in case severe pain and ibuprofen 400mg if the pain persisted. documentation of intake of either placebo or analgesic will be done by the patient.

Eligibility criteria:
inclusion criteria: * no medical history * patients suffering from symptomatic irreversible pulpitis * patients suffering from apical periodontitis * patients requiring porcelain fused to metal crown exclusion criteria: * patients who were not suitable for conventional root canal treatment * multirooted teeth

Keywords: occlusal reduction
beta-blocker vs. ic antiarrhythmic drug for pvc

Conditions: Premature Ventricular Complex

Summary: the standard medical therapy of idiopathic premature ventricular complex consists of beta blocker and ic antiarrhythmic agent. however, the difference in the efficacy of two drugs has not been well investigated. this prospective randomized study aimed to compare the efficacy of beta-blocker and ic antiarrhythmic agent in the treatment of symptomatic patients with idiopathic premature ventricular complex.

a premature ventricular complex is frequently observed in routine clinical practice and patients without structural heart disease occasionally have benign outcomes. the initial therapy of symptomatic premature ventricular complex is medical treatment with beta-blocker, calcium channel blocker or antiarrhythmic agents. however, no large prospective study has been performed to identify the difference in the efficacy between drugs. the current study was designed to compare the efficacy between beta-blocker and class ic antiarrhythmic agent. patient with symptomatic pvc more than 6000 episode per 24 hours is included. exclusion criteria are evidence of structural heart disease, coronary heart disease, significant bradycardia or use of a concomitant antiarrhythmic agent. patients are randomized into beta-blocker group (propranolol) and ic antiarrhythmic agent group (propafenone). response to the drug is evaluated after 2 months from randomization by 24 hours holter and questionnaire. the primary endpoint is more than 80% pvc reduction or pvc burden less than 300 beats per 24 hours. the secondary endpoint is patient's symptom evaluated by questionnaire and the number of pvcs measured in 24 hours holter.

Eligibility criteria:
inclusion criteria: * over 19 years old \>6000 pvcs/24hrs exclusion criteria: * left ventricular ejection fraction \<50% or significant valvular disease (≥moderate) history of coronary artery disease use of a concomitant antiarrhythmic agent significant bradycardia
τreatment standards and outcomes of patients with er/pr positive, her2-negative metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: • to capture the treatment patterns and clinical characteristics of patients with er/pr positive, her2-negative mbc in greece

* to capture the treatment patterns and clinical characteristics of patients with er/pr positive, her2-negative mbc in greece * to evaluate the outcome of patients per treatment line (objective response, progression free survival, time to disease progression per line of therapy), overall survival * to record adverse events per line of therapy * to recording of the causes of treatment discontinuation per line of therapy

Eligibility criteria:
inclusion criteria: * women with histological confirmed er/pr positive, her2-negative mbc * age \>18 years old * patients initiating first or second line therapy for er/pr positive, her2-negative mbc * adequate hematologic, renal and hepatic function * signed informed consent (icf) exclusion criteria: * active malignancy other than mbc * active infection
thiamin against robust ibd fatigue

Conditions: Fatigue

Summary: patients with inflammatory bowel disease (ibd), disease in remission and chronic fatigue will receive oral thiamine treatment for 4 weeks in a rct, cross-over study.

patients with inflammatory bowel disease (ibd), disease in remission and chronic fatigue will receive high dose oral thiamine treatment for 4 weeks in a rct, cross-over study. after the high dose treatment period, participants will be randomized to 3 months treatment with thiamine 300mg/day or placebo.

Eligibility criteria:
inclusion criteria: * inflammatory bowel disease * disease in remission * chronic fatigue exclusion criteria: * co-morbidity that can explain fatigue * pregnancy * non-compliance to the study procedures * possible surgery in the study period

Keywords: inflammatory bowel disease fatigue thiamine vitamin b1
sleep and rehearsal-driven memory in epilepsy

Conditions: Epilepsy; Memory Consolidation

Summary: memory consolidation transforms unstable memory traces into lasting representations, a process enhanced by both sleep and rehearsal during learning. rehearsal is thought to accelerate consolidation by inducing memory reactivations that resemble those occurring during sleep. however, the respective mechanisms of sleep- and rehearsal-induced consolidation-and their potential interactions-remain poorly understood, especially in patients with temporal lobe epilepsy, where rehearsal might help compensate for memory deficits linked to hippocampal dysfunction, and where sleep may exacerbate epileptic activity. the coresom-epi study aims to compare the effects of rehearsal and sleep on memory consolidation in patients undergoing video-eeg monitoring. participants will learn "object-place" associations under two conditions (single versus repeated encoding), with memory tested immediately and again after a 12-hour delay. this delay will either include a full day awake or a night of sleep, allowing direct comparison of sleep- and rehearsal-related consolidation effects. each participant will perform the task twice, with "wake" and "sleep" condition, in a balanced order. as a preliminary phase of the crimes study (anr-dfg 2024), coresom-epi will help assess how sleep and rehearsal influence memory consolidation in epilepsy. it will also serve to adapt the behavioral task for clinical use, paving the way for a future intracranial eeg investigations that will explore the neural networks involved and their modulation by epileptic activity.


Eligibility criteria:
inclusion criteria: * patient with epilepsy (any type of epilepsy) * hospitalized for video-eeg recording lasting at least 4 days * aged 18-65 years exclusion criteria: * major cognitive impairment other than memory deficit * refusal to participate * pregnant women, women in labor or nursing mothers * persons deprived of their liberty by judicial or administrative decision * persons under psychiatric care * persons admitted to a health or social institution for purposes other than research * adults under legal protection (guardianship, curatorship)

Keywords: epilepsy memory consolidation sleep reharsal reactivation
clinical study of ptfe covered stent for treating portal hypertension

Conditions: Portal Hypertension

Summary: to validate the safety and efficacy of tips (transjugular intrahepatic portosystemic shunt) using ptfe covered stent in the treatment of portal hypertension.

this trial is a prospective multi-center single-arm confirmatory study. a total 177 subjects will be enrolled in multiple centers nationwide. subjects who meet the trial requirements, fulfill the inclusion criteria, voluntarily participate in the study, and provide informed consent will undergo tips using the ptfe covered stent for the treatment of portal hypertension. follow-up assessments will be conducted at discharge, as well as at 30 days, 90 days, 180 days and 360 days postoperatively. secondary endpoint measures include surgical success rate, all-cause mortality, device/procedure-related mortality, incidence of adverce events, and serious adverse event rates. the trial aims to comprehensively assess the safety and efficacy of the ptfe covered stent produced by enlight medical technologies (shanghai) co., ltd..

Eligibility criteria:
inclusion criteria: subjects must meet all of the following criteria to be eligible for this study: * age 18-85 years; * cirrhotic portal hypertension required for tips; * willingness to comply with the protocol requirements and ata collection procedures, ability to understand the purpose of the trial, voluntary participation, and signing of informed consent by the subject or legal guardian. exclusion criteria: subjects meeting any of the following criteria are not eligible for this study: * concomitant chronic heart or lung disease; * presence or suspicion of active systemic, hepatobiliary or ascitic fluid infection; * severe hepatic failure (with bilirubin levels of \>51.3μmol/l or child-pugh \>13 or meld \>18); * hepatic encephalopathy; * coagulation disorders; * portal vein thrombosis; * allergies to device components; * extrahepatic malignancy; * pregnant or brestfeeding women or those planning pregnancy during the trial peroid; * intending or currently participating in another interventional clinical trial; * other conditions deemed inappropriate for participation in this study by the investigator.

Keywords: transjugular intrahepatic portosystemic shunt
the effect of prolonged inspiratory time on gas exchange during robot-assisted laparoscopic surgery with steep trendelenburg position : a crossover randomized clinical trial

Conditions: Prostatic Neoplasm; Urinary Bladder Neoplasm

Summary: gas exchange disturbance frequently occurs in steep trendelenburg position during robot-assisted laparoscopic prostatectomy or cystectomy. due to increased intrathoracic pressure and absorbed carbon dioxide (co2) gas insufflated into abdominal cavity, hypercapnia as well as hypoxia may occur. inverse ratio ventilation or prolonged inspiratory time during mechanical ventilation has been reported to be improve gas exchange in adult respiratory distress syndrome. the investigators attempt to test the hypothesis that prolonged inspiratory time may improve the gas exchange during robot-assisted laparoscopic urologic surgery.

gas exchange disturbance frequently occurs in steep trendelenburg position during robot-assisted laparoscopic prostatectomy or cystectomy. due to increased intrathoracic pressure and absorbed co2 gas insufflated into abdominal cavity, hypercapnia as well as hypoxia may occur. inverse ratio ventilation or prolonged inspiratory time during mechanical ventilation has been reported to be improve gas exchange in adult respiratory distress syndrome. the investigators attempt to test the hypothesis that prolonged inspiratory time (i:e ratio = 1:1) may improve the gas exchange during robot-assisted laparoscopic urologic surgery.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status class i-ii and scheduled for an elective robot-assisted laparoscopic radical prostatectomy or robot-assisted laparoscopic radical cystectomy * patients who voluntarily decides to participate in the trial and has agreed in written informed consent exclusion criteria: * patients with the anatomical abnormalities of respiratory system(abnormal airway anatomy, severe scoliosis, post-pneumonectomy state), severe chronic respiratory diseases, chronic obstructive pulmonary disease (copd), asthma, heart failure, obesity ( body mass index \[bmi\] \> 30kg/m2), severe hepatic failure or renal failure
financial incentives and weight loss in failed bariatric surgery

Conditions: Obesity; Obesity Recidivism

Summary: this national, prospective, multicenter, and randomized study seeks to evaluate the effect of financial incentives on weight loss in individuals who experience weight regain following bariatric surgery. the study also aims to conduct a cost-utility analysis to measure the effectiveness of the intervention and assess the potential budgetary implications if it were to be implemented on a wider scale.

our intervention is based on the principle of "contingency management" whereby financial rewards are contingent upon meeting specific weight loss targets. to assess the effectiveness of this approach, patients who have experienced weight regain after bariatric surgery will be randomly assigned to one of three groups. group 1 will receive the standard care that includes setting a weight-loss target based on the weight achieved at 12 months post-bariatric surgery following the standard multidisciplinary follow-up at the inclusion center. group 2 will receive the same treatment as the control group (group 1), but with an additional financial incentive if the weight loss target (corresponding to the weight they reached 12 months after bariatric surgery) is achieved 12 months after inclusion. group 3 will receive the same treatment as the control group (group 1), but the financial incentive will be proportional to the actual weight loss achieved relative to the weight loss target (corresponding to the weight they reached 12 months after bariatric surgery). the study will include a standard post-bariatric surgery follow-up visits scheduled at 6, 12, 18, and 24 months, as per routine practice. at the 12-month visit, participants will be eligible to receive a financial incentive based on their arm assignment and the extent of weight loss achieved. after the 12-month visit, participants will not receive any additional financial incentives until the 24-month visit.

Eligibility criteria:
inclusion criteria: * male or female over 18 years of age * patients with a history of adjustable gastric banding, sleeve gastrectomy, gastric bypass or sadi-sleeve surgery * patient with a post-operative delay of more than 2 years * patient who has gained ≥10% of the maximum weight lost * patient still obese (body mass index ≥ 30 kg/m²) after surgery exclusion criteria: * pregnant women * women of childbearing potential planning a pregnancy during the first year of the study * persons under legal protection (safeguard of justice, guardianship, curatorship, etc.)

Keywords: bariatric surgery financial incentive
study of hemospray for lower gastrointestinal hemorrhage

Conditions: Colonic Diverticula; Angiodysplasia; Colonic Polyp

Summary: this study is to evaluate the performance of hemospray for the teatment of nonvariceal lower gastrointestinal bleeding.


Eligibility criteria:
inclusion criteria: * patient in which hemospray is used to treat an endoscopically confirmed nonvariceal lower gi bleed requiring hemostasis exclusion criteria: * less than 19 years old * unwilling or unable to sign and date the informed consent * pregnant, lactating or planning to become pregnant within 30 days of the procedure * contraindicated to undergo colonoscopy medical/endoscopic exclusion criteria * actual or suspected lower gi perforation or fistula * bleeding originating from inflammatory bowel disease (e.g., crohn's disease or ulcerative colitis) * actual or suspected ischemic colitis or infectious colitis * unable to visualize site of active bleeding (such as suspected diverticular bleed where source is unable to be identified) * unable to treat active site of bleeding (e.g., bleeding site cannot be reached by the colonoscope)

Keywords: gastriointestinal lower gastriointestinal digestive hemostasis recurrent bleeding hemospray
study of high-dose rate (hdr) monotherapy for low and intermediate risk prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine the clinical efficacy and toxicity of high-dose rate (hdr) brachytherapy as monotherapy for the treatment of low risk and intermediate risk prostate cancer.


Eligibility criteria:
inclusion criteria: * biopsy proven adenocarcinoma of the prostate * clinical stage t1c, t2a or t2b * psa less than 20 ng/ml * gleason score 6 or 7 exclusion criteria: * age less than 18 years * clinical stage t2c, t3 ou t4 * clinical stage n1 * clinical stage m1 * prostate specific antigen (psa) more than 20 ng/ml * gleason score 8 or higher * ipss score 19 or higher with alpha-blockers * past radiation therapy to the pelvis * history of collagen vascular disease * history of inflammatory bowel disease * bilateral hip prosthesis

Keywords: brachytherapy monotherapy hdr
host response to pessaries in microbial communities of the postmenopausal vagina

Conditions: Stress Urinary Incontinence; Prolapse

Summary: the ability to determine the postmenopausal vaginal environment and the impact of pessary use could help to maximize pessary therapy and non-surgical treatment for such a prevalent problem.

the study will advance the care of elderly patients through providing data to maximize non-surgical options to those at high risk for having surgery and its attending morbidity. in characterizing substantive differences in the vaginal environment of successful and unsuccessful pessary users, the investigators can identify elderly patients at higher risk of adverse events with pessary use as well as novel targets for the pharmacologic treatment of the altered vaginal microbiota and endogenous amp levels, potentially allowing patients to continue with non-surgical therapies rather than pursuing surgical intervention.

Eligibility criteria:
inclusion criteria: * must be english speaking * appropriate for pessary treatment * pelvic floor conditions such as pop (with or without the presence of a uterus), stress urinary incontinence, urge urinary incontinence, or any combination of the above. exclusion criteria: * a history of current, symptomatic vaginal stricture * a history of current, radiation therapy, * or current treatment with auto-immune suppression agents. * if they have eroded mesh in the vagina from prior pelvic floor surgery
alcohol screening and preoperative intervention research study - 2

Conditions: Alcohol Drinking

Summary: this sequential, multiple assignment, randomized trial will test treatments designed to reduce alcohol use before and after surgery to promote surgical health and long-term wellness.


Eligibility criteria:
inclusion criteria: 1. completed consent form, baseline survey, and enrollment phone call 2. willingness to comply with all study procedures and availability for the duration of the study 3. scheduled for select major elective surgery (non-cancer) in the next 5-12 weeks 4. score ≥ 5 on the alcohol use disorders identification test-concise (audit-c) based on research linking this score with increased risk of surgical complications 5. access to a smart device or computer access with internet or wi-fi connection throughout the study period exclusion criteria: 1. exclude participants enrolled in another research study focused on alcohol use 2. history of severe alcohol withdrawal 3. unable to speak, understand, or read english

Keywords: surgery